Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer

Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer

<p>Supplementary Data</p>

Сохранить в:

Библиографические подробности
Главный автор:	Alex Chehrazi-Raffle (17079582) (author)
Другие авторы:	Hanna Tukachinsky (15030806) (author), Eamon Toye (15925708) (author), Smruthy Sivakumar (15053536) (author), Alexa B. Schrock (15047582) (author), Hannah E. Bergom (15925687) (author), Hedyeh Ebrahimi (17079585) (author), Sumanta Pal (17079588) (author), Tanya Dorff (17079591) (author), Neeraj Agarwal (15021102) (author), Brandon A. Mahal (17079594) (author), Geoffrey R. Oxnard (15047597) (author), Justin Hwang (15925675) (author), Emmanuel S. Antonarakis (14971443) (author)
Опубликовано:	2025
Предметы:	Cancer Therapeutic Research and Development Methods and Technology Computational Methods Gene expression profiling Genitourinary Cancers Prostate cancer Liquid Biopsy Translational Research
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Supplementary Figure 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
по: Alex Chehrazi-Raffle (17079582)
Опубликовано: (2025)

Figure 1 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
по: Martin Sjöström (14845882)
Опубликовано: (2025)

Figure 2 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
по: Martin Sjöström (14845882)
Опубликовано: (2025)

Figure 3 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
по: Martin Sjöström (14845882)
Опубликовано: (2025)

Figure 4 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
по: Martin Sjöström (14845882)
Опубликовано: (2025)

Figure 5 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
по: Martin Sjöström (14845882)
Опубликовано: (2025)

Figure 6 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
по: Martin Sjöström (14845882)
Опубликовано: (2025)

Figure 7 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
по: Martin Sjöström (14845882)
Опубликовано: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
по: Martin Sjöström (14845882)
Опубликовано: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
по: Martin Sjöström (14845882)
Опубликовано: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
по: Martin Sjöström (14845882)
Опубликовано: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
по: Sofie H. Tolmeijer (15313251)
Опубликовано: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
по: Sofie H. Tolmeijer (15313251)
Опубликовано: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
по: Sofie H. Tolmeijer (15313251)
Опубликовано: (2025)

Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
по: Cloud P. Paweletz (14960112)
Опубликовано: (2025)

Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
по: Whitney L. Hensing (16461978)
Опубликовано: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
по: Francesca Orzan (15055579)
Опубликовано: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
по: Francesca Orzan (15055579)
Опубликовано: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
по: Francesca Orzan (15055579)
Опубликовано: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
по: Kala Visvanathan (14952973)
Опубликовано: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
по: Kala Visvanathan (14952973)
Опубликовано: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
по: Kala Visvanathan (14952973)
Опубликовано: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
по: Kala Visvanathan (14952973)
Опубликовано: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
по: Kala Visvanathan (14952973)
Опубликовано: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
по: Emil Christensen (15054394)
Опубликовано: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
по: Emil Christensen (15054394)
Опубликовано: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
по: Stephanie Lheureux (16797697)
Опубликовано: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
по: Stephanie Lheureux (16797697)
Опубликовано: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
по: Stephanie Lheureux (16797697)
Опубликовано: (2025)

Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
по: Stephanie Lheureux (16797697)
Опубликовано: (2025)

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
по: Stephanie Lheureux (16797697)
Опубликовано: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
по: Iris van 't Erve (15054503)
Опубликовано: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
по: Andrew A. Davis (15030032)
Опубликовано: (2025)

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
по: N. Ari Wijetunga (15056183)
Опубликовано: (2025)

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
по: N. Ari Wijetunga (15056183)
Опубликовано: (2025)

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
по: N. Ari Wijetunga (15056183)
Опубликовано: (2025)

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
по: N. Ari Wijetunga (15056183)
Опубликовано: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
по: Morten Lapin (15056728)
Опубликовано: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
по: Morten Lapin (15056728)
Опубликовано: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
по: Morten Lapin (15056728)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_314pd3a6qnejsmv8bk7ledj28u